ABM-TKI is a tool, employing agent-based model (ABM), to simulate brain tumor growth that includes an EGFR signaling pathway together with a related cell-cycle pathway, angiogenesis and tyrosine kinase inhibitors (TKIs) treatment. The users can apply this tool to predict the responses of brain cancer to TKIs, and to reveal the dual role of angiogenesis during TKI treatment.
- Windows / MacOsX / Linux
:: MORE INFORMATION
Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: incorporating EGFR signaling pathway and angiogenesis.
Sun X, Zhang L, Tan H, Bao J, Strouthos C, Zhou X.
BMC Bioinformatics. 2012 Aug 30;13:218. doi: 10.1186/1471-2105-13-218.